CD28 and neoplasm: We showed for both CAR specificities that T cells with the CD28 co-stimulatory endodomain migrated better to the tumor and had superior anti-tumor effect, while T cells with 4-1BB co-stimulus (except HER2-SS-4-1BB/ζ) failed to expand at the tumor site and induce tumor regression.